FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. VPI/95-09 DIV		SERIAL NO. 09/431,469		
1 Parcond	SUPPLEMENTAL INFORM		CLOSURE	APPLICANT David M. Ar	rs mistead et al.		
B 24 2004 6	STATEMENT BY APPLICANT			FILING DATE November 1, 1999		GROUP 1631	
EXAMINER		U.S. PAT	ENT DOCUME	NTS			
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
m	<sup>7</sup> 4,833,233	5/23/89	Carter	530	363	8/20/87	
mon	5,025,388	6/18/91	Cramer, III	364	496	8/26/88	
more	5,331,573	7/19/94	Balaji	364	496	12/14/90	
usu	5,353,236	10/4/94	Subbiah	364	499	4/23/92	
		FOREIGN P	ATENT DOCU	MENTS T	T	1	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	ATION NO
MO	WO94/25860	11/10/94	PCT	G01N	24/00	•	
	×			* x			
	OTHER DOCUME	NTS (Includin	g Author, Title,	Date, Pertiner	nt Pages, Etc.)		
EXAMINER INITIAL M			٠	,			· ·
m	Andrus, M.B. and Schreib and Calcineurin" J. Am. (				cyclic Ligand Tha	at Bridges F	KBP12
892 1/4/01 MSM	Barford, D. and Keller, J.C., "Co-crystallization of the Catalytic Subunit of the Serine/Threonine Specific Protein Phosphatase 1 from Human in Complex with Microcystin LR", <u>J. Mol. Biol.</u> , 235, pp. 763-766 (1994)						
Man	Bierer, B.E. et al., "Cyclosporin A and FK506: Molecular Mechanisms of Immunosuppression and Probes for Transplantation Biology" Curr. Opinion in Immunology, 5, pp. 763-773 (1993).						
_MS M	Caffrey, M.V. et al. "Synthesis And Evaluation Of Dual Domain Macrocyclic FKBP12 Ligands" <u>Bioorg.</u> Med. Chem. Lett., 4, pp. 2507-2510 (November, 1994).						
w	Campbell, I.D. and Dwek, R.A., "Diffraction" in <u>Biological Spectroscopy</u> , The Benjamin/Cummings Publishing Company, Menlo Park, CA, pp. 299-326 (1984).						
12 14101 M	Griffith, J.P. et al., "X-Ray Structure of Calcineurin Inhibited by the Immunophilin-Immunosuppressant FKBP12-FK506 Complex", Cell, 82, pp. 507-522 (1995)						
Norg	Guerini, D. and Klee, C.B., "Cloning of Human Calcineurin A: Evidence for Two Isozymes and Identification of a Polyproline Structural Domain", <u>Proc. Natl. Acad. Sci. USA</u> , 86, pp. 9183-9187 (1989)						
MA	Holt, D.A. et al., "Design, Crystal Structures of The	Synthesis, an	d Kinetic Evalu	ation of High-	Affinity FKBP Lig	ands and th	ne X-ra
EXAMINER	Mc M	1		DA	TE CONSIDERE	ED <sub>Q</sub> / <sub>S</sub>	1. 11

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

	· · · · · · · · · · · · · · · · · · ·			
FORM PTO-1	449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. VPI/95-09 DIV	SERIAL NO. 09/431,469	
SECOND SURPLEMENTAL INFORMATION DISCLOSURE COTATEMENT BY APPLICANT FEB 2 4 2004		APPLICANTS David M. Armistead et al.		
		FILING DATE November 1, 1999	GROUP 1631	
	OTHER DOCUMENTS (Including Author, Title, I	Date, Pertinent Pages, Etc.)		
EXAMINE BASS				
man	Hubbard, M.J. and Klee, C.B., "Functional Domain Stru Proteolysis", <u>Biochemistry</u> , 28, pp. 1868-1874 (1989)	ucture of Calcineurin A: Mapping	y by Limited	
m	Kajihara, A. et al., "Protein Modelling Using a Chimera Reference Protein Derived From Exons" <u>Protein Eng.</u> , 6, pp. 615-620 (1993).			
192 114101 MM	Kissinger, C.R. et al., "Crystal Structures of Human Calcineurin and the Human FKBP12-FK506-Calcineurin Complex", Nature, 378, pp. 641-644 (1995)			
mor,	Kunz, J. and Hall, M.N. "Cyclosporin A, FK506 and Rapamycin: More Than Just Immunosuppression" TIBS, 18, pp. 334-338 (1993).			
my	Sharma, R.K. and Wang, J.H., "Calmodulin and Ca <sup>2+</sup> -Dependent Phosphorylation and Dephosphorylation of 63-kDa Subunit-Containing Bovine Brain Calmodulin-Stimulated Cyclic Nucleotide Phosphodiesterase Isozyme" J. Biol. Chem., 261, pp. 1322-1328 (1986).			
M				
not	Uhlin, U. et al., "Crystallization and Crystallographic Investigations of Ribonucleotide Reductase Protein R1 from Escherichia coli" FEBS Lett., 336, pp. 148-152 (1993).			
mon	Villafranca, J.E. et al., "Protein Serine/Threonine Phosphatases", <u>Current Opinion in Biotech.</u> , 7, pp. 387-402 (1996)			
non	Wilson, K.P. et al. "Comparative X-ray Structures of the Major Binding Protein for the Immunosuppressant FK506 (Tacrolimus) in Unliganded Form and in Complex with FK506 and Rapamycin" Acta Cryst., D51, pp. 511-521 (July, 1995).			

**EXAMINER** 

MG Moun

DATE CONSIDERED 8/3//06

ATTY. DOCKET NO. VPI/95-09 DIV

U.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE

APPLN. NO.

09/431,469

APPLICANTS CONFIRMATION NO. INFORMATION DISCLOSURE David Armistead et 8756 STATEMENT BY APPLICANT **RECEIVED** al. FILING DATE GROUP November 1, 1999 1631 OCT 1 5 2003 CENTER 1600/2900 U.S. PATENT DOCUMENTS FILING DATE EXAMINER DOCUMENT DATE NAME CLASS SUBCLASS IF INITIAL NUMBER APPROPRIATE FOREIGN PATENT DOCUMENTS EXAMINER TRANSLATION DOCUMENT RTAG COUNTRY CLASS SUBCLASS NUMBER INITIAL YES NO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) EXAMINER INITIAL Balbes, L.M., et al., "A Perspective of Modern Methods in Computer-Aided Drug Design, " in "Reviews in Computational Chemistry, " K.B. Lipkowitz and D.B. Boyd, Eds., VCH Publishers, New York, 5: 337-379 (1994). Bartlett, P.A., et al., "CAVEAT: A Program to Facilitate the Structure-Derived Design of Biologically Active Molecules," in "Molecular Recognition in Chemical and Biological Problems, "S.M. Roberts, Ed., Royal Society of Chemistry, Special Publication No. 78: 182-196 (1989). Böhm, H.-J., "The Computer Program LUDI: A New Method for the De Novo Design of Enzyme Inhibitors," J. Comp. Aid. Molec. Design, 6: 61-78 (1992). Cohen, N.C., et al., "Molecular Modeling Software and Methods for Medicinal Chemistry," J. Med. Chem., 33: 883-894 (1990).

EXAMINER

FORM PTO-1449

MG Moron

DATE CONSIDERED 7/21/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

OTPE

## U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.	
VPI/95-09 DIV	09/431,469	
APPLICANTS David Armistead et al.	CONFIRMATION NO. 8756	
FILING DATE	GROUP	
November 1, 1999	1631	

Eisen, M.B., et al., "HOOK: A Program for Finding Novel Molecular Architectures that Satisfy the Chemical and Steric Requirements of a Macromolecule Binding Site," Proteins Struct. Funct. Genet., 19: 199-221 (1994).
Gillet, V., et al., "SPROUT: A Program for Structure Generation," J. Comp. Aid. Molec. Design, 7: 127-153 (1993).
Goodford, P.J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules," J. Med. Chem., 28: 849-857 (1985).
Goodsell, D.S., and Olson, A.J., "Automated Docking of Substrates to Proteins by Simulated Annealing," Proteins Struct. Funct. Genet., 8: 195-202 (1990).
Guida, W.C., "Software for Structure-Based Drug Design," Curr. Opin. Struct. Biology, 4: 777-781 (1994).
Kuntz, I.D., et al., "A Geometric Approach to Macromolecule-Ligand Interactions," J. Mol. Biol., 161: 269-288 (1982).
Lauri, G. and Bartlett, P.A., "CAVEAT: A Program to Facilitate the Design of Organic Molecules," J. Comp. Aid. Molec. Design, 8: 51-66 (1994).
Martin, Y.C., "3D Database Searching in Drug Design," J. Med. Chem., 35: 2145-2154 (1992).
Miranker, A., and Karplus, M., "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method," Proteins Struct. Funct. Genet., 11: 29-34 (1991)
Meng, E.C., et al., "Automated Docking with Grid-Based Energy Evaluation,"  Journal of Computational Chemistry, 13: 505-524 (1992).
Navia, M.A. and Murcko, M.A., "Use of Structural Information in Drug Design," Current Opinion in Structural Biology, 2: 202-210 (1992).
Nishibata, Y., and Itai, A., "Automatic Creation of Drug Candidate Structures Based on Receptor Structure. Starting Point for Artificial Lead Generation." Tetrahedron, 47: 8985-8990 (1991).

examiner

Ma your

DATE CONSIDERED 4/2/04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTY. DOCKET NO.	APPLN. NO.		
VPI/95-09 DIV	09/431,469		
APPLICANTS David Armistead et al.	CONFIRMATION NO. 8756		
FILING DATE	GROUP		
November 1, 1999	1631		

BLANK	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.